Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems

• Status: Terminated
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Voriconazole and caspofungin acetate may control invasive fungal infections in patients who have weakened immune systems.

PURPOSE: This phase II trial is studying how well giving voriconazole together with caspofungin acetate works in treating invasive fungal infections in patients with weakened immune systems.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: OHSU Knight Cancer Institute
• Collaborator: National Cancer Institute (NCI)
• Treatments: Caspofungin; Echinocandins; Voriconazole

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of probable or definite invasive fungal infection with 1 of the following organisms:

• Aspergillus species

• Fusarium species

• Scedosporium species (Pseudallescheria boydii)

• Other dematiaceous molds

• The following diagnosis are not allowed:

• Zygomycetes (Mucor or Rhizopus species)

• Chronic aspergillosis

• Aspergilloma

• Allergic bronchopulmonary aspergillosis

• Must be immunocompromised

PATIENT CHARACTERISTICS:

Age

• 18 and over

Performance status

• Not specified

Life expectancy

• At least 72 hours

Hematopoietic

• Not specified

Hepatic

• AST < 5 times upper limit of normal (ULN)

• Bilirubin < 5 times ULN

• Alkaline phosphatase < 5 times ULN

• No Child-Pugh class C cirrhosis

Renal

• Creatinine clearance ≥ 50 mL/min

Pulmonary

• No mechanical ventilation

Other

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No hypersensitivity to azoles, caspofungin acetate, or their components

• No history of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• More than 14 days since prior therapeutic antifungal therapy of ≥ 1 week duration

• More than 14 days since prior and no concurrent administration of any of the following medications:

• Terfenadine

• Astemizole

• Cisapride

• Pimozide

• Quinidine

• Sirolimus

• Rifampin

• Carbamazepine

• Long-acting barbiturates

• Rifabutin

• Ergot alkaloids (i.e., ergotamine and dihydroergotamine)